{"id":22792,"date":"2019-07-16T00:00:00","date_gmt":"2019-07-16T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2019\/07\/16\/non-vitamin-k-oral-anticoagulants-may-be-best-for-early-stage-ckd\/"},"modified":"2019-07-17T16:07:41","modified_gmt":"2019-07-17T16:07:41","slug":"non-vitamin-k-oral-anticoagulants-may-be-best-for-early-stage-ckd","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2019\/07\/16\/non-vitamin-k-oral-anticoagulants-may-be-best-for-early-stage-ckd\/","title":{"rendered":"Non-Vitamin K Oral Anticoagulants May Be Best for Early-Stage CKD"},"content":{"rendered":"<h3>Benefit-risk profile superior to vitamin K antagonists for early-stage chronic kidney disease<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>TUESDAY, July 16, 2019 (HealthDay News) &#8212; Non-vitamin K oral anticoagulants (NOACs) have a superior benefit-risk profile to that of vitamin K antagonists (VKAs) for patients with early-stage chronic kidney disease (CKD), according to a review published online July 16 in the <i>Annals of Internal Medicine<\/i>.<\/p>\n<p>Jeffrey T. Ha, M.B.B.S., from the University of New South Wales in Sydney, and colleagues examined the benefits and harms of VKAs and NOACs in adults with CKD stages 3 to 5. Data were included for 45 trials involving 34,082 participants who received anticoagulation for atrial fibrillation (AF; 11 trials), venous thromboembolism (VTE; 11 trials), thromboprophylaxis (six trials), prevention of dialysis access thrombosis (eight trials), and cardiovascular disease other than AF (nine trials).<\/p>\n<p>The researchers found that in AF, NOACs reduced the risks for stroke or systemic embolism and hemorrhagic stroke (risk ratios, 0.79 [95 percent confidence interval, 0.66 to 0.93] and 0.48 [95 percent confidence interval, 0.30 to 0.76], respectively) compared with VKAs. The effects of NOACs on recurrent VTE or VTE-related death were uncertain compared with VKAs (risk ratio, 0.72; 95 percent confidence interval, 0.44 to 1.17). NOACs seemed to reduce major bleeding risk compared with VKAs in all trials combined (risk ratio, 0.75; 95 percent confidence interval, 0.56 to 1.01).<\/p>\n<p>&#8220;NOACs had a benefit-risk profile superior to that of VKAs in patients with early-stage CKD, with significant reductions in stroke or systemic embolism and hemorrhagic stroke in AF,&#8221; the authors write. &#8220;However, evidence is insufficient to recommend widespread use of VKAs or NOACs to improve clinical outcomes in patients with advanced CKD and dialysis-dependent end-stage kidney disease.&#8221;<\/p>\n<p>Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n<p><a href=\"https:\/\/annals.org\/aim\/article-abstract\/2738158\/benefits-harms-oral-anticoagulant-therapy-chronic-kidney-disease-systematic-review\" target=\"_new\" rel=\"noopener noreferrer\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/annals.org\/aim\/article-abstract\/2738159\/balancing-benefits-harms-oral-anticoagulation-chronic-kidney-disease-what-does\" target=\"_new\" rel=\"noopener noreferrer\">Editorial (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2019 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Benefit-risk profile superior to vitamin K antagonists for early-stage chronic kidney disease<\/p>\n","protected":false},"author":6,"featured_media":22829,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-22792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/22792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=22792"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/22792\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/22829"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=22792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=22792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=22792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}